Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi.
about
The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudiVaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaquesStructure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory AntibodyStructural Characterization of Apical Membrane Antigen 1 (AMA1) from Toxoplasma gondiiCharacterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparumIndependent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites.Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion.Comparative genomic analysis and phylogenetic position of Theileria equiIdentification of a highly antigenic linear B cell epitope within Plasmodium vivax apical membrane antigen 1 (AMA-1)Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic VariationSafety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaquesAMA1 and MAEBL are important for Plasmodium falciparum sporozoite infection of the liverInduction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes.Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides.Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes.Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccineBinding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1Mimotopes of apical membrane antigen 1: Structures of phage-derived peptides recognized by the inhibitory monoclonal antibody 4G2dc1 and design of a more active analoguePhase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malariaIdentification and characterization of the Plasmodium yoelii PyP140/RON4 protein, an orthologue of Toxoplasma gondii RON4, whose cysteine-rich domain does not protect against lethal parasite challenge infectionPhase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.Lack of association between maternal antibody and protection of African infants from malaria infection.Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challengeImmune responses of NIH mice infected with avirulent and virulent strains of Plasmodium chabaudi adami single and mixed infections.A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites.Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.Peptide inhibitors of the malaria surface protein, apical membrane antigen 1: identification of key binding residuesImmunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy.posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.Conditional expression of Toxoplasma gondii apical membrane antigen-1 (TgAMA1) demonstrates that TgAMA1 plays a critical role in host cell invasionExpression of Babesia equi merozoite antigen 1 in insect cells by recombinant baculovirus and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay.Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trialsImmunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.Toxoplasma gondii homologue of plasmodium apical membrane antigen 1 is involved in invasion of host cells.Specificity of the protective antibody response to apical membrane antigen 1
P2860
Q27318798-98720C59-E2AE-4B54-9323-C9FC362B8E89Q27336448-FA11AE27-A088-458F-8797-FC45B0A039FEQ27648686-38E62881-0500-42E7-91AC-BAA8199BAC27Q27660294-8F8CD27E-C7F7-4F2F-9BE2-F04CF2338EF4Q27972927-87E15625-51D1-4748-8E3B-C6852D268578Q27973516-A57FF0DB-1C08-4FCF-B651-C79F138F543AQ27973517-71FF3710-5D78-4474-A353-7E3DC4D60C3CQ28278882-86BFA08C-C8AA-46BA-BAA0-0B3AB6A26BE0Q28478668-AADFB716-5EBE-4871-8FC7-7A0CF03C5171Q28554439-AE2D0908-6238-48DB-917C-C86E8B35A1C5Q28742239-7CB616E1-3B61-4318-8AA3-2B554EC70B5DQ30044955-692D297A-1989-4B0C-A330-E7E3DA462A25Q30783460-3B0BA370-39FF-4B45-A821-B01073EB278DQ30863749-CDA11731-7212-4B9E-8F8D-18CDF4AE179AQ30942598-8025DE4C-6F0B-484B-951B-DA1F4808895DQ30967137-C5F6DBE3-C904-488D-BD60-D7148BCD2267Q31030126-03FFDDDE-7607-4880-B915-DB3F50101765Q33197101-9C8709CD-4660-493B-8000-95EC27F53B7CQ33214292-F2C0C873-0077-403A-9724-C60158D20DA3Q33223740-A0E82148-E609-4C66-B1A5-DB33E720795FQ33261308-A4212A59-D799-45D4-84CB-EEAB7A34AD36Q33359552-50E36981-E2DD-4739-86D2-6886281F6FD2Q33361102-26E7BBD5-82ED-4BC0-B90D-861BBE5A07F6Q33434412-1A478C0C-2CF4-4D28-B84B-437718AD0B95Q33558449-7C6075FC-ABE0-406B-9E25-B2380E2692F6Q33592503-AA5DEDF7-0C57-4F7D-8361-628D8EA16613Q33593204-DBD741DB-3CA6-4548-B1DC-FBE5D45D38A2Q33746686-B74F6FCC-9CB5-46ED-80DF-9391E4EBAC70Q33756139-DDA56248-4DDE-4F6D-884E-63CEF378CC14Q33772752-402A84E0-F7C8-400D-9074-FB16C26FE462Q33788027-E6DB41BC-E5D1-4334-AD60-BF7FD299477AQ33835382-8294358B-9BBD-4DFA-A23A-23C67CE6E48AQ33883252-B243C572-E3E7-4BD1-A113-7FBDB4A0605BQ33938442-AE08713B-E851-45AA-B5C0-914388EB7ECBQ33971298-1E4D9A6E-78E2-446F-9675-E8EB0228FD40Q34001568-B9967383-2F5B-43D9-937E-B76194306757Q34004431-8371AEA5-EB51-4A6D-B384-2F0566B4C204Q34004960-79005569-993C-4034-BAF9-41EFFF1876A8Q34005337-DD1D9631-44E5-4EBA-897E-AA41F365367EQ34007362-633898F1-A860-4AC1-9604-40DB240D5074
P2860
Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@en
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@nl
type
label
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@en
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@nl
prefLabel
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@en
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@nl
P2093
P1433
P1476
Immunisation with recombinant ...... tion with Plasmodium chabaudi.
@en
P2093
P304
P356
10.1016/S0264-410X(97)88331-4
P407
P577
1998-01-01T00:00:00Z